Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses - PubMed (original) (raw)
Clinical Trial
. 1999 Aug 1;94(3):902-8.
Affiliations
- PMID: 10419880
Free article
Clinical Trial
Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses
A H Rook et al. Blood. 1999.
Free article
Abstract
Progression of cutaneous T-cell lymphoma (CTCL) is associated with profound defects in cell-mediated immunity and depressed production of cytokines, which support cell-mediated immunity. Because we have observed marked defects in interleukin-12 (IL-12) production in CTCL and because IL-12 is critical for antitumor cytotoxic T-cell responses, we initiated a phase I dose escalation trial with recombinant human IL-12 (rhIL-12) where patients received either 50, 100, or 300 ng/kg rhIL-12 twice weekly subcutaneously or intralesionally for up to 24 weeks. Ten patients were entered: 5 with extensive plaque, 3 with Sezary syndrome, and 2 with extensive tumors with large cell transformation. One patient with Sezary syndrome dropped out after 1 week for personal reasons. Subcutaneous dosing resulted in complete responses (CR) in 2 of 5 plaque and partial responses (PR) in 2 of 5 plaque, and 1 of 2 Sezary syndrome (overall response rate CR+PR 5 of 9, 56%). A minor response also occurred in 1 of 5 plaque patients. Intralesional dosing resulted in individual tumor regression in 2 of 2 patients. Biopsy of regressing lesions showed a significant decrease in the density of the infiltrate in all cases and complete resolution of the infiltrate among those with clinical lesion resolution. An increase in numbers of CD8-positive and/or TIA-1-positive T cells were observed on immunohistochemical analysis of skin biopsy specimens obtained from regressing skin lesions. Adverse effects of rhIL-12 on this regimen were minor and limited and included low-grade fever and headache. One patient discontinued rhIL-12 at week 6 because of depression. These results suggest that rhIL-12 may augment antitumor cytotoxic T-cell responses and may represent a potent and well-tolerated therapeutic agent for CTCL.
Similar articles
- The role for interleukin-12 therapy of cutaneous T cell lymphoma.
Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, Foss F, Shapiro M, Kuzel TM, Olsen EA, Vonderheid EC, Laliberte R, Sherman ML. Rook AH, et al. Ann N Y Acad Sci. 2001 Sep;941:177-84. doi: 10.1111/j.1749-6632.2001.tb03721.x. Ann N Y Acad Sci. 2001. PMID: 11594571 Clinical Trial. - A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.
Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, Laliberté RJ, Ryan JL, Zonno K, Rook AH. Duvic M, et al. J Am Acad Dermatol. 2006 Nov;55(5):807-13. doi: 10.1016/j.jaad.2006.06.038. Epub 2006 Sep 8. J Am Acad Dermatol. 2006. PMID: 17052486 Clinical Trial. - Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB. Gollob JA, et al. J Clin Oncol. 2003 Jul 1;21(13):2564-73. doi: 10.1200/JCO.2003.12.119. J Clin Oncol. 2003. PMID: 12829677 Clinical Trial. - Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2.
Rook AH, Kuzel TM, Olsen EA. Rook AH, et al. Hematol Oncol Clin North Am. 2003 Dec;17(6):1435-48, ix. doi: 10.1016/s0889-8588(03)00109-6. Hematol Oncol Clin North Am. 2003. PMID: 14710894 Review. - Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Jawed SI, et al. J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049. J Am Acad Dermatol. 2014. PMID: 24438969 Review.
Cited by
- Advances in the understanding and treatment of Cutaneous T-cell Lymphoma.
Bakr FS, Whittaker SJ. Bakr FS, et al. Front Oncol. 2022 Nov 24;12:1043254. doi: 10.3389/fonc.2022.1043254. eCollection 2022. Front Oncol. 2022. PMID: 36505788 Free PMC article. Review. - Gene expression analysis in Interleukin-12-induced suppression of mouse mammary carcinoma.
Shi X, Liu J, Xiang Z, Mitsuhashi M, Wu RS, Ma X. Shi X, et al. Int J Cancer. 2004 Jul 1;110(4):570-8. doi: 10.1002/ijc.20145. Int J Cancer. 2004. PMID: 15122590 Free PMC article. - The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.
Kelly-Sell MJ, Kim YH, Straus S, Benoit B, Harrison C, Sutherland K, Armstrong R, Weng WK, Showe LC, Wysocka M, Rook AH. Kelly-Sell MJ, et al. Am J Hematol. 2012 Apr;87(4):354-60. doi: 10.1002/ajh.23112. Epub 2012 Feb 24. Am J Hematol. 2012. PMID: 22367792 Free PMC article. - Intratumoral IL-12 Gene Therapy Inhibits Tumor Growth In A HCC-Hu-PBL-NOD/SCID Murine Model.
Zhou ZF, Peng F, Li JY, Ye YB. Zhou ZF, et al. Onco Targets Ther. 2019 Sep 20;12:7773-7784. doi: 10.2147/OTT.S222097. eCollection 2019. Onco Targets Ther. 2019. PMID: 31571927 Free PMC article. - Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects.
Gokhale MS, Vainstein V, Tom J, Thomas S, Lawrence CE, Gluzman-Poltorak Z, Siebers N, Basile LA. Gokhale MS, et al. Exp Hematol Oncol. 2014 Apr 11;3(1):11. doi: 10.1186/2162-3619-3-11. Exp Hematol Oncol. 2014. PMID: 24725395 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials